ARCA Biopharma Target Price vs. Cash Per Share
| ABIO Stock | USD 3.58 0.10 2.87% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 1.02 | 1.08 |
|
|
For ARCA Biopharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of ARCA Biopharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well ARCA Biopharma utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between ARCA Biopharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of ARCA Biopharma over time as well as its relative position and ranking within its peers.
ARCA |
Is ARCA Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ARCA Biopharma. If investors know ARCA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ARCA Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.37) | Return On Assets (0.12) | Return On Equity (0.16) |
The market value of ARCA Biopharma is measured differently than its book value, which is the value of ARCA that is recorded on the company's balance sheet. Investors also form their own opinion of ARCA Biopharma's value that differs from its market value or its book value, called intrinsic value, which is ARCA Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ARCA Biopharma's market value can be influenced by many factors that don't directly affect ARCA Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ARCA Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if ARCA Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ARCA Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
ARCA Biopharma Cash Per Share vs. Target Price Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining ARCA Biopharma's current stock value. Our valuation model uses many indicators to compare ARCA Biopharma value to that of its competitors to determine the firm's financial worth. ARCA Biopharma is rated fifth in target price category among related companies. It is rated below average in cash per share category among related companies fabricating about 0.46 of Cash Per Share per Target Price. The ratio of Target Price to Cash Per Share for ARCA Biopharma is roughly 2.17 . At this time, ARCA Biopharma's Cash Per Share is very stable compared to the past year.Comparative valuation analysis is a catch-all model that can be used if you cannot value ARCA Biopharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for ARCA Biopharma's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the ARCA Biopharma's earnings, one of the primary drivers of an investment's value.ARCA Cash Per Share vs. Target Price
ARCA Biopharma | = | 7.0 |
Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
ARCA Biopharma |
| = | 3.22 X |
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
ARCA Cash Per Share Comparison
ARCA Biopharma is currently under evaluation in cash per share category among related companies.
ARCA Biopharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in ARCA Biopharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, ARCA Biopharma will eventually generate negative long term returns. The profitability progress is the general direction of ARCA Biopharma's change in net profit over the period of time. It can combine multiple indicators of ARCA Biopharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 0.00 | 0.00 | |
| Operating Income | -7.3 M | -7.7 M | |
| Income Before Tax | -5.3 M | -5.6 M | |
| Total Other Income Expense Net | 2 M | 2.1 M | |
| Net Loss | -5.3 M | -5.6 M | |
| Income Tax Expense | -111 K | -116.5 K | |
| Net Loss | -5.4 M | -5.7 M | |
| Non Operating Income Net Other | 32.2 K | 30.6 K | |
| Net Loss | -8.9 M | -9.4 M | |
| Interest Income | 1.8 M | 1.9 M | |
| Net Interest Income | 1.8 M | 1.9 M | |
| Change To Netincome | 504.9 K | 314.5 K | |
| Net Loss | (0.37) | (0.39) | |
| Income Quality | 0.94 | 0.92 | |
| Net Income Per E B T | 0.84 | 0.75 |
ARCA Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on ARCA Biopharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of ARCA Biopharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the ARCA Biopharma's important profitability drivers and their relationship over time.
Use ARCA Biopharma in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ARCA Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ARCA Biopharma will appreciate offsetting losses from the drop in the long position's value.ARCA Biopharma Pair Trading
ARCA Biopharma Pair Trading Analysis
The ability to find closely correlated positions to ARCA Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ARCA Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ARCA Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ARCA Biopharma to buy it.
The correlation of ARCA Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ARCA Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ARCA Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ARCA Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your ARCA Biopharma position
In addition to having ARCA Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Emerging Markets ETFs Thematic Idea Now
Emerging Markets ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Emerging Markets ETFs theme has 21 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Emerging Markets ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. To learn how to invest in ARCA Stock, please use our How to Invest in ARCA Biopharma guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Complementary Tools for ARCA Stock analysis
When running ARCA Biopharma's price analysis, check to measure ARCA Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ARCA Biopharma is operating at the current time. Most of ARCA Biopharma's value examination focuses on studying past and present price action to predict the probability of ARCA Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ARCA Biopharma's price. Additionally, you may evaluate how the addition of ARCA Biopharma to your portfolios can decrease your overall portfolio volatility.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |
To fully project ARCA Biopharma's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of ARCA Biopharma at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include ARCA Biopharma's income statement, its balance sheet, and the statement of cash flows.